The value of an embedded qualitative study in a trial of a second antidepressant for people who had not responded to one antidepressant: understanding the perspectives of patients and general practitioners. by Chew-Graham, CA et al.
RESEARCH ARTICLE Open Access
The value of an embedded qualitative
study in a trial of a second antidepressant
for people who had not responded to one
antidepressant: understanding the
perspectives of patients and general
practitioners
Carolyn A. Chew-Graham1* , Thomas Shepherd1, Heather Burroughs1, Katie Dixon1 and David Kessler2
Abstract
Background: Depression is the leading cause of disability worldwide, and is a major contributor to the overall
global burden of disease. The number of prescriptions for antidepressants has risen dramatically in recent years yet
up to 50% of patients who are treated for depression with antidepressants do not report feeling better as a result
of treatment, and do not show the desired improvement on depression measures. We report a qualitative study
embedded in a trial of second antidepressant for people who had not responded to one antidepressant, exploring
the acceptability of a combination of antidepressants from the perspectives of both patients and practitioners,
together with experiences of participating in a clinical trial.
Methods: A qualitative study embedded in a randomized controlled trial investigating the effectiveness and cost-
effectiveness of combining mirtazapine with Serotonin-Noradrenaline Reuptake Inhibitor (SNRI) or Selective
Serotonin Reuptake Inhibitor (SSRI) antidepressants versus SNRI or SSRI therapy alone (the MIR trial). 59 interviews
were conducted with people who declined to participate in the trial, people who completed the study and people
who withdrew from the intervention, and 16 general practitioners.
Results: Across the data-sets, four main themes were identified: the hard work of managing depression,
uncertainties over the value of a second antidepressant, help-seeking at a point of crisis, and attainment and
maintenance of a hard-won equilibrium.
Conclusions: Exploring reasons for declining to participate in a trial of a second antidepressant in people who had
not responded to one antidepressant suggests that people who are already taking one antidepressant may be
reluctant to take a second, being wary of possible side-effects, but also being unconvinced of the logic behind
such a combination. In addition, people describe being in a state of equilibrium and reluctant to make a change,
reflecting that this equilibrium is ‘hard-won’ and they are unwilling to risk disturbing this. This makes some people
reluctant to enrol in a clinical trial. Understanding a patient’s view on medication is important for GPs when
discussing antidepressants.
Trial registration: MIR Trial Registration: ISRCTN 06653773.
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Background
Depression is the leading cause of disability worldwide,
and is a major contributor to the overall global burden
of disease [1]. Currently, depression is thought to affect
approximately one in ten of the population [2] and the
prevalence of depressive symptoms may increase with
age [3].. Depression is more common in those people
with long-term physical conditions [4].
GPs have been found to be good at recognizing moder-
ate to severe depression [5], but they may be more likely
to do so when patients present with psychosocial as op-
posed to somatic symptoms [6, 7]. A large WHO natural-
istic study in 15 cities around the world (and in 11
languages), found that patients whose depression went
unrecognized had milder depression at baseline and were
not found to be at a disadvantage in terms of outcome [8].
Nevertheless a significant minority of people who might
benefit from treatment remains undetected [9, 10].
People with depression are typically managed in pri-
mary care, and in the United Kingdom, depressive symp-
toms are the third most common reason to consult a
general practitioner (GP) [11]. The National Institute for
Health and Care Excellence (NICE) guideline on the
treatment of depression [12] provides evidence-based
guidance to primary and secondary care practitioners, in
England, on the treatment of depression and promotes a
stepped care model of treatment, recommending the
least intensive therapies as a first line intervention. This
is often a ‘talking treatment’ or psychological therapy
[13] but referral to psychological therapists can be prob-
lematic due to waiting times for, and lack of availability
of, appropriate and acceptable services [14]. The guide-
line suggests that where patients have moderate to se-
vere, recurrent or chronic sub-threshold depression,
antidepressants are indicated.
The number of prescriptions for antidepressants has
risen dramatically in recent years; increasing by 7.2%
(3.8 million items) between 2013 and 2014, in the NHS
[15]. Indeed, antidepressants have shown a greater in-
crease in the volume of prescribing in 2014 than drugs
for any other therapeutic area, with over 57 million pre-
scriptions being issued in England in 2014, at a cost of
£265 million.
However, many patients do not respond to antidepres-
sants. The STAR*D study (Sequenced Treatment Alter-
natives to Relieve Depression) found that half of those
treated did not experience at least a 50% reduction in
depressive symptoms following 12–14 weeks of treat-
ment with a single antidepressant [16]. A substantial
proportion of those who take their antidepressants in an
adequate dose and for an adequate period, do not ex-
perience a clinically meaningful improvement in their
depressive symptoms. This can be termed treatment re-
sistant depression (TRD).
For patients who are deemed to have not responded to
one antidepressant, the NICE guideline [12] suggests
that General Practitioners (GPs) should re-consider the
treatment option if there has been no response after 4 to
6 weeks of antidepressant monotherapy. The guideline
describes a number of pharmacological strategies to at-
tempt after inadequate response to initial treatments in-
cluding combining antidepressants.
The ‘MIR’ trial evaluated the addition of mirtazapine
to a Serotonin-Noradrenaline Reuptake Inhibitor (SNRI)
or Selective Serotonin Reuptake Inhibitor (SSRI) anti-
depressant over placebo in primary care patients with
TRD [17]. The embedded qualitative study, embedded in
the MIR trial, reported here aimed to explore patients’
perspectives on being invited to participate in a trial [17]
of a second antidepressant for TRD and the acceptability
of combination drug treatments for depression to pa-
tients and GPs.
Patients’ health beliefs are central to reaching agree-
ment about treatment between patient and practitioner,
requiring a discussion which is inclusive of and con-
siders the views and beliefs of both parties [18]. Further-
more, Patient beliefs and attitudes also influence
adherence to antidepressant medication [19, 20]. Previ-
ous literature reporting patients’ views on the manage-
ment of depression suggest that some patients prefer
psychological treatments to medication, [21, 22] but
these preferences vary depending on a number of factors
including age, gender and their own understanding of
depression [23, 24]. Negative views on antidepressants
include concerns that they are addictive [25], and older
people may be particularly reluctant to take antidepres-
sants [26, 27].
It cannot be assumed that patients already on anti-
depressant medications will have either a positive atti-
tude to, or a good understanding of, that treatment or
will therefore be willing to take another antidepressant if
their depressive symptoms remain. Evidence suggests
that some patients using SSRI antidepressants would
prefer to stop but are afraid to do so [20] and that when
considering stopping the use of SSRIs, patients have a
number of concerns about cessation which clinicians
should attend to. [28, 29] In a meta-ethnographic syn-
thesis of qualitative evidence it was found that patients
were heavily engaged in negotiating a ‘medication career’
or ‘moral career’ [30] making choices about how to
proceed with treatment and sense-making around their
illness. This study also emphasizes the vital role that
GPs play in facilitating patient decision-making, through
discussion to aid understanding and meaning-making
around depression and treatment experiences.
The views of patients who decline to take part in re-
search can highlight salient attitudes about interven-
tions. Barnes et al. [31] reported, in their qualitative
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study exploring views of people who had declined to
participate in a trial of cognitive behavioural therapy
(CBT) for Treatment Resistant Depression, that the ac-
ceptability of the trial intervention was an important fac-
tor in determining whether patients chose to participate
in the trial.
O’Caithain, Thomas & Drabble et al. (2014) empha-
sises that the value of qualitative research to randomized
controlled trials includes ‘improving the external validity
of trials and facilitating interpretation of trial findings’
[32]. This paper reports a qualitative study embedded in
the MIR trial, and aims to contribute to the understand-
ing of TRD, as well as the acceptability of a combination
of antidepressants from the perspectives of both patients
and practitioners, with implications for how the inter-
vention may be received more widely by patients and
GPs in primary care.
Methods
Ethical approval was obtained from the South East
Wales Research Ethics Committee (12/WA/0353).
We conducted semi-structured interviews with people
who were invited to participate in the MIR trial [17], but
declined, trial participants (those who completed the
trial, and who withdrew) to generate in-depth data on
perspectives of participating in the trial, reasons for
completion or withdrawal. In addition, we interviewed
GPs to explore their experiences of participating in the
MIR trial, perspectives on managing people with depres-
sion, with a focus on perspectives of antidepressant
prescribing.
Participants were recruited to the MIR trial [17] from
106 general practices in Bristol, North Staffordshire and
Shropshire, Hull, York and Exeter. A screening question-
naire was posted to 2299 potential participants. Respon-
dents who declined to participate could give a reason on
a form which provided closed questions to indicate their
reason(s) for declining. There was also a free text re-
sponse box for respondents to give additional details
about or alternative reasons for declining. Respondents
were also given an option to indicate their willingness to
be contacted to be interviewed about their reasons for
declining. The questionnaire was brief, to maximise the
likely response. These data were collected throughout
the recruitment period.
Recruitment
If respondents indicated that they were willing to be
contacted about their reasons for declining participation,
this data was stored on a database, accessed by the trial
team to invite a sample of willing respondents, catego-
rized as ‘decliners’ to participate in a semi-structured
interview. Sampling from within the ‘decliner’ popula-
tion was purposive, on the basis of gender, age,
geographic location and reasons for declining to partici-
pate, to gain maximum variation within the sample. Free
text responses were also used to direct sampling when
respondents had selected ‘other’ as a closed response
and when details were given in the free text box which
would indicate their suitability or unsuitability to be
contacted about their reasons for declining. Once identi-
fied as suitable for contact, the research assistant (KD)
made telephone contact with the respondent, gave de-
tails about the purpose of the call, the relationship of the
qualitative study within the MIR trial and their rights as
a potential participant of the study to confidentiality and
to withdraw their consent at any time. They were then
asked whether they had further questions and whether
they would be willing to participate in a telephone inter-
view. If verbal consent was given these interviews were
usually conducted at the time of the initial phone call or
arrangements were made to call the respondent at a
more convenient time.
Sampling of trial participants was carried out at 12
weeks (once primary outcome measures assessed), tak-
ing gender, age and geographical location to gain max-
imum possible variation within the available sample.
Participants were advised at the12 week assessment by
the researcher that they may be contacted by study team
to discuss their experiences of participation in the trial.
The research assistant (KD) received regular reports
from the trial teams on participants who had reached
the primary outcome measure, and following review of
the participant record, would attempt to contact partici-
pants, where the contact notes suggested it was appro-
priate to do so. Where there had been any serious or
adverse events or where the participant had declined
further contact after the primary outcome measure,
these individuals were not invited to participate in the
qualitative study. Participants were initially contacted by
telephone and asked whether they would be willing to
take part in an interview to discuss their experiences
of being in the trial. If a trial participant agreed, an
information sheet with further details of the study
was sent to the participant and a provisional date for
a face-to-face interview was made (usually 1–2 weeks
after the date of the phone call to allow the informa-
tion sheet time to arrive and the participant to con-
sider the content).
When a participant withdrew from the trial, KD
reviewed the participant record with the researcher or
research nurse who had visited the participant, and con-
tacted the ‘withdrawer’ to gain consent to an interview.
If the person agreed, an information sheet was sent and
a provisional date for a telephone interview was made.
‘Withdrawers’ were asked to send their consent forms
back to the research team prior to the interview which
was conducted by telephone.
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GPs were recruited from the 106 practices participat-
ing with the MIR trial. Sampling of GP practices was
purposive and selection based on the geographical loca-
tion of the practice, gender and experience of the GP, to
give maximum variation in the available population.
Sampling was also contingent on whether the practice
had patients who had been randomized to the MIR trial.
GPs and practice managers were initially contacted by
email, with the information sheet as an attachment, in-
viting them to discuss their experiences of managing
people with depression and views of using a combination
of anti-depressants. If there was no response to the
email, telephone calls were made to the practice. If a GP
expressed interest in participating in an interview, the
research assistant (KD) arranged a telephone interview
at a time that was convenient to the GP.
Data generation
Informed consent to participate in the qualitative study
was obtained from all participants in the study. People
invited to take part in interviews about their reasons for
declining to participate in the MIR trial, were provided
with a short questionnaire during the trial recruitment
phase on which to indicate consent to be contacted
about their reasons for non-participation. When these
patients were contacted by telephone, they were asked
to confirm that they had consented to taking part in a
telephone interview and for their verbal consent to rec-
ord the telephone interview. Participants were reminded
about their rights as a participant to confidentiality and
to withdraw their consent at the beginning and the end
of the conversation respectively. This procedure for
gaining consent to conduct and record telephone inter-
views was also followed when contacting GPs for tele-
phone interviews for the study. Interviews with GP
participants and decliners were conducted via telephone.
Patients participating in the trial were sent an informa-
tion sheet in the post after their 12 week outcome meas-
ure had been taken by the researcher or research nurse,
outlining information about participation in the qualita-
tive study. For those participants who agreed to an inter-
view, each participant was asked to sign a written
consent form to indicate their consent to participate,
and the researcher confirmed this consent further ver-
bally before commencing the interview. The majority of
interviews with patient participants were held face to
face with the participant, in their own homes.
Data were generated using semi-structured interviews
with participants conducted either via the telephone (pa-
tients who declined participation in the trial and general
practitioners) or during face to face interviews (patients
who completed or withdrew from the trial).
Topic guides for each group of participants (decliners,
patients and GPs) were produced prior to the
commencement of the first interviews and were
amended and adapted in response to initial analysis of
interviews and after discussion within the research team.
The process was iterative throughout the period of data
generation to better explore the concepts and themes
which emerged as being important to the interviewees
and required more in depth examination during subse-
quent interviews.
Data generated from each of these data sets were col-
lected during each interview by the qualitative research as-
sistant, using a digital audio recorder. Audio files were
transcribed verbatim by an authorized transcription com-
pany and transcripts were stored securely by the research
assistant in accordance with standard operating proce-
dures. Each interview was checked against the
audio-recording, cleaned and anonymized prior to analysis.
Data generation was continued until data saturation
within each data-set was considered, by the research
team, to have been achieved.
Data analysis
Thematic analysis of the data [33] was conducted inde-
pendently by authors CCG, HB and KD in the first in-
stance. Subsequently the three members of the
qualitative research team discussed their individual ana-
lysis and themes were agreed through discussion [33].
The three researchers were from different professional
backgrounds (academic primary care, health services re-
search and anthropology) which increases trustworthi-
ness of analysis. [34]. Transcripts were read and re-read,
themes arising during data generation and analysis
within the team, and the topic guides modified itera-
tively as data collection and analysis progressed.
The qualitative research team met regularly to discuss
and agree coding, revisiting the data from each dataset
(and from analysis of other data-sets) in an iterative man-
ner to verify coding and themes generated from these
codes. This process was repeated until it was agreed that
each individual data-set had reached saturation. Analysis
was initially conducted within each data-set, then compar-
isons carried out across the datasets, in order to identify
similarities and differences (disconfirmatory evidence).
Discussion was continued until consensus was reached
amongst the larger research team and PPIE group.
NVIVO 10 [35] was used to store data and aid analysis.
The qualitative research team worked with a Patient
and Public Involvement and Engagement (PPIE)
group to discuss transcripts from the data-sets. The
aim was to add value to the analysis with the lay
partners adding value to the analysis by bringing their
own perspectives and identifying further areas for the
researcher to look for in the interviews [36]. Four
meetings were held with the PPIE group over the
course of data generation and analysis.
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Members of the study PPIE group were recruited from
members of the Keele Research User Group (RUG) which
consists of over 100 members who contribute to all stages
of development of studies. The study team invited people
to participate in the study PPIE group if they had personal
experience, or experience as a carer, of depression.
Two or three interview transcripts, or extracts of tran-
scripts, were circulated prior to the PPIE meeting, and
then the transcripts were discussed during the meeting,
exploring what meaning the PPIE members gave to cer-
tain data extracts, and the research team offering their
interpretations and checking this out with the PPIE
group. The PPIE group members were supported by a
RUG Advisor at each meeting.
Results
We will present reasons given by people invited but who
declined to participate in the MIR trial.
We will then describe the participants in the qualita-
tive study, followed by key themes across the data-sets.
Reasons given for declining to participate in the
MIR trial:
The reasons that people gave for not wanting to par-
ticipate in the MIR trial are listed in Table 1.
The commonest reason for declining was not want-
ing to take part in a trial (49%). 36% of people invited
indicated that they did not want to take mirtazapine;
it is not known if this was because of prior experi-
ence of being prescribed this anti-depressant. Not
wanting to take more than one antidepressant was
given by 20% people invited to participate in the MIR
trial. Interestingly, 17% of people suggested that they
were not taking an antidepressant – even though they
were being prescribed and SSRI or SNRI according to
their GP records; 39% people said they planned to
stop taking the current antidepressant.
Qualitative study participants
A total of 59 interviews were conducted; 23 with de-
cliners (Mean duration = 11min 27 s) (Table 2); 23 com-
pleters and withdrawers (Mean duration = 47 min 35 s)
(Table 3), and 14 with General Practitioners (mean dur-
ation 19 min 31 s) (Table 4).
Key themes across the data-sets
Key themes presented in this manuscript include ‘the
hard work of managing depression’, uncertainties over
the value of a second antidepressant, help-seeking at a
point of crisis, and attainment and maintenance of a
hard-won equilibrium.
Illustrative data will be presented with the gender and
age of the patient participant given as identifiers in the
case of trial participants (completers and withdrawers)
and those who declined to participate (decliners). Data
from GP transcripts will be identified with numbers
reflecting the chronological order in which the inter-
views were conducted.
The hard work of managing depression
Respondents reflected on the history of their depressive
symptoms, and there were rich descriptions of endeav-
ours to manage their mental-health, including a broad
range of self-management strategies and help-seeking.
Many respondents described delays in recognizing the
cause of their depression, outlining repeated investiga-
tion for physical problems until a diagnosis of depression
was achieved by default:
“Erm, what it went back to was – I think it was
postnatal depression, it started, and I didn’t realise
what it was. Erm, that was [...] so that was 20 years
ago and I thought I’d got ME or, or MS or something,
because I, I, physically, couldn’t walk. I wasn’t
particularly unhappy, but I, I was physically fatigued
really, really fatigued. And I struggled with that for
years, going for tests, and one thing and another, and
it never came to anything, because it was
depression.”[Female, 55, decliner].
Once recognized as depression, respondents reported
that they had tried numerous strategies and life-style
Table 1 Reasons for declining participation in the MIR trial
Reason N = 4702
(25%)a
a I do not want to take part in a research study 2298 (49%)
b I plan to stop taking my current antidepressant 1822 (39%)
c I do not want to take mirtazapine 1692 (36%)
d I do not want to take a placebo 1328 (28%)
e I only want to take one antidepressant 936 (20%)
f I’m not taking antidepressants 818 (17%)
g I am too busy 463 (10%)
h I am not depressed 323 (7%)
i Other reason(s) 1321 (28%)
a Individuals were able to indicate more than one reason, thus percentages do
not add up to 100%
Table 2 Decliners
Site Participant
total
Gender
Male
Gender
Female
Age Range
(years)
Bristol 7 1 6 27–66
Exeter 6 2 4 40–54
Keele 6 3 3 32–76
Hull/York 4 2 2 35–68
Totals 23 8 15
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changes to manage their own symptoms, including exer-
cise and diet, seeking support from family and friends,
taking steps to ease the pressure on themselves, and pur-
suing psychological and alternative therapies:
“Well I’d been on websites to look at the condition….to
look at what I could do, such as the omega-3, eating
well, exercising, getting as much light as you can…all
those sort of things.” [Male, 57, decliner].
Respondents described the effort involved in ‘carrying on’:
“you feel as if you don’t have as much confidence and
you don’t feel erm what – erm like you don’t want to
participate in things that you did want to participate
in and you’re not really bothered about things.
Obviously you are, but that’s how it makes you feel,
you know. And also, like you haven’t got as much
energy as you did have and you keep putting things
off… ‘Oh yeah, I’ll do it tomorrow.’ And yet, I mean,
I’m a very busy person. I have a full-time job and I
work at least 40 h a week, so I mean I do hide it well,
it’s on the inside I would say.” [Female 59, completer].
All respondents indicated the hard work involved in
trying to manage their symptoms and endeavouring to
find something that might help:
“...I’ve been doing a lot of meditation and, sort of,
pursuing the mindfulness route […] I think to get out
of depression, you have to probably put in a lot of
different things in place to be able to tackle the things
that have got you there, [okay] and exercise and eating
well or trying to eat well even though I didn’t have an
appetite.” [Female, 37, decliner].
“there’s a group called (names third sector group), to
get in contact with them, and see what they would
suggest, as well, and what they could do to help. And
also, er, through work, I contacted, hmm, another
similar group…and they directed me to, like, er, a
series of one-to-ones or just, sort of, counselling, sort of
soft counselling, or something [okay], just talking to
somebody, talking therapy [uh-huh]. Er, a via (a
different third sector group), I ended up doing a, erm,
what was it called, which is more to do with, sort of,
the food and overeating side of things, and I ended up
having cognitive behavioural therapy with somebody,
as well. Erm that was more along the line to control
eating, which was, as opposed to dealing with
depression in a particular way [okay]. But, yeah, I
came away that day, from the doctor’s, with
antidepressants.” [Male, 55, completer].
Some respondents described an initial reluctance to
take anti-depressants, but having got over this, suggested
that they had come to terms with the need to use drugs
to manage their mood. However, many respondents
expressed concerns over the length of time that they
would have to take their current antidepressant and
were resistant taking a second antidepressant.
“I felt […] that I didn’t wanna get involved in
taking tablets for six, nine, 12 months. I’m already
six months into taking them now [hmm], which is
longer than I thought I would be…I thought, ‘Oh, I’ll
get rid of it. I’ll be okay. I’ll have a few months or
I’ll have a couple of months off. I’ll be back to my
normal self,’ but it hasn’t worked like that..Erm, and
whether another antidepressant would help I really
don’t know.” [Male, 55, decliner].
Such reluctance was sometimes due to a fear of (add-
itional) side-effects:
“I didn’t want to start with the side effects what I got
from the first one [uh-huh]. I didn’t want to start with
new side effects and things.” [Female, 4, decliner].
Whilst GPs described managing people with depres-
sion as ‘the bread and butter of general practice’, they
reflected on the complexity of the work involved in the
assessment of a patient:
“I mean all of it is history taking initially, finding out
a little bit about the, the, the physical problems, social
Table 3 Completers and Withdrawers
Site Participant
total
Gender
Male
Gender
Female
Age range
(years)
Bristol 11 5 6 32–63
Exeter 3 2 1 56–83
Keele 5 2 3 38–69
Hull/York 4 0 4 49–52
Total 23 9 14
Table 4 General Practitioners
Site Participant
total
Gender
Male
Gender
Female
Bristol 5 4 1
Exeter 5 4 1
Keele/ N Staffs/Shropshire 2 2 0
Hull/York 2 1 1
Total 14 11 3
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problems and obviously their mental health problems.
There might be more significant social connotations.
So they might have alcohol related problems or drug
use problems and things like that so that can make
things a bit more challenging” [GP04].
“you can’t give a global answer to that actually
because it’s incredibly tailored individual …to
individual patient circumstances and patient beliefs
[…] so I’m - you know, I just think it’s - it’s just very
individual I think we all adopt different consultation
styles for different patients, don’t we?” [GP02].
This multifaceted and individual assessment of pa-
tients who presented with depressive symptoms or on-
going depression, described by some GPs as a large
component of their workload, was also described as one
that can feel like a ‘battle’ and at times overwhelming:
“Erm, so it’s, it’s inevitably a battle [yeah]. Well, not a
battle, it’s a challenge to, to relate to the patient in the
way that they understand. That’s what we do for a
living, isn’t it? [Hmm] I suppose.” [GP12].
In addition, GPs described the complexity in negotiat-
ing management of depression with patients:
“erm I think it’s - some of it’s about previous response
or lack of previous depression, really. [okay] Erm the,
the - I think then that’s looking at the broader context
of what the patient’s like, whether it’s a personality
disorder erm and whether it’s err circumstantial, you
know, whether it’s - there’s, there’s - it - there’s quite a
few things that feed into that, really” [GP10].
Maintaining equilibrium
The invitation to participate in a trial was described as pos-
ing a challenge, as managing depression was already seen as
a series of complex decisions, with continued reflection and
self-monitoring required. Respondents indicated that they
were declining to take part because they feared disturbing
the sense of balance they had achieved with their current
antidepressant medication. The potential work involved in
participation was felt to be a challenge to current stability:
“Because you know when you suddenly drop and you
don’t know why? [Hmm] Erm, I’ve had a drop recently, so
that, I don’t know what that was, but I had a drop
recently, and I had to, sort of, look again at what I was
doing [yeah]. Erm, so, adding something, changing
something, is a bit scary for me [uh-huh] because I was
feeling good, and I like feeling okay.” [Female, 53, decliner].
“but for me, taking something, erm, potentially taking
something that could disrupt the way I am when I’m,
you know, feel I’m on a steady level, I, I didn’t really
want to, to take that risk.” [Female, 27, completer].
Other respondents, whilst recognizing that something
else may be necessary to help them manage their symp-
toms, expressed a preference for talking treatments:
“….I’m on quite a low dose really, 20 milligrams of,
erm, Citalopram, and I think it was doing the job it
needed to do […] to get me to point where I could look
at some issues.” [Female, 39, decliner].
A number of interview participants who had declined to
consent to participate in the trial stated that, had they been
offered combination treatment at a point of crisis, when
they felt out of balance and unable to cope, they might
have agreed to take part in the trial because of their des-
peration to overcome their depression. In the following ex-
tract, the decliner participant is responding to a question
from the researcher about whether they would have con-
sidered taking two antidepressants if they hadn’t felt better
on one tablet. Their response suggests that if they had
been ‘at rock bottom’ taking two tablets would not have
been an issue if it offered the chance of getting better.
“…I needed to do whatever it took to, you know, get well
again, quite simply. So I, I would do whatever it takes.
When you - I think when you really hit rock bottom you
are prepared to do whatever it takes and I have
absolute faith in my doctor” [Female, 42, decliner].
One participant makes an extreme comparison, but
makes the same point about being willing to accept
whatever was necessary to escape being depressed.
“I think, I think if you’d caught me when I was
depressed, I would have taken anything to be
honest, I would have done anything to get out of it
[…] in the first instance I struggled for a few weeks
erm, thinking oh I can get out of this and it’s
alright, it’s temporary and then it gets to a point
where two, three weeks down the line, I just
thought, I can’t deal with this, I’m on a sinking
ship, so I think if the study had been then, and
someone had offered me, you know, I don’t know, a
shot of heroin a day to get out of it, I would have
done it!” [Female, 38, completer].
Why would another tablet help?
Some respondents expressed scepticism about the
‘chemical imbalance’ story that they felt had been told to
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them, to explain why a tablet would help their mood.
Why a second anti-depressant would help if the first had
not was questioned:
(I): “…would you have had any concerns about taking
two antidepressants?”
(P): “Erm, no, I don’t think so…but I should wonder
why I suppose I hadn’t had any, er, sort of beneficial
reaction and maybe had to go to the doctors again
and say it doesn’t seem to be working terribly well,
what else can we do” [Male, 76, decliner].
Respondents described the protracted sequence of try-
ing out other antidepressants, increases in the dosage of
their medication which had been either been ineffective
or had worked for a limited time, then seemed to stop
working, and referrals to talking therapies. Hoping that
this trial would be another option for them to regain a
sense of wellbeing was prevalent in accounts of these
participants’ experiences:
“I felt that the antidepressants, I’d already been on,
you know, I was given 20 milligrams, and then they
were increased to 40 [uh-huh], and yet I still wasn’t
feeling, I wasn’t really feeling, er, 100% [uh-huh]. So I
just felt that that [taking part in the trial] could be a
different way of trying to get things, trying to get me a
bit more better, you know” [Male, 54, completer].
Participants in the trial were keen to get back to a level
of coping and wellbeing they had experienced previously.
They described that they were no longer feeling a benefi-
cial effect from their medication and in some cases had
sought out another option from their GP. The partici-
pant in the following extract gives an account of ap-
proaching her GP asking for them to ‘do something’:
“I was taking sertraline erm probably from quite a
while, really; about four months or so. And I felt they
hadn’t made enough difference. [okay] Erm so I went
back to the doctor and I was really worried and I said,
‘Look, I need some - either to up this medication or
change it, do something” [Female, 49, completer].
The opportunity to participate in the MIR trial came
at a time when they were seeking an alternative option
to help them manage their depression.
Patients who withdrew from the trial did so either be-
cause of side-effects of because they felt that they had
regained their equilibrium:
“I think the medication that I was on, got me, you
know, on an acceptable level, you know. I’m not as bad
as I was […] And then you get to a stage where yeah,
things are acceptable. You just accept things and you
just carry on” [Female, 69, withdrawer].
“Had my weight gain not been so severe I would’ve
gone on longer taking the drug – and I told her (the
researcher) that. I said to her that I couldn’t warrant
having great thoughts and then dying of a cardiac
arrest [laughs] because I’d put on so much weight. I
have weight issues anyway, so it was just like the
balance wasn’t right for me by the end of it” [Female,
36, completer - withdrew after un blinding].
Although some GPs described a level of confidence in
prescribing two antidepressants, all expressed caution
about how long such a combination should be contin-
ued. Some speculated on how they might try to reduce
one anti-depressant in a combination, but none of the
GPs interviewed reported experience of stopping one in
the combination:
“I daresay we’d reduce one to zero, first of all, and
see how it goes, and then reduce the other to zero
[uh-huh]. I don’t think I would stop them both at
the same time [yeah]. I don’t know [uh-huh], but I
think I would, I’m sure I would do that, actually.
I’d, I’d choose one and say, ‘Well, how are you
doing?’ And, ‘We’re gonna have to start reducing
these now [yeah], and I would suggest that,’ er, ‘we
get you off one first of all, for a few weeks, and see
how you feel, and then withdraw the other one
slowly.”[GP 12].
All GPs expressed concern about patients remaining
on two anti-depressants, suggesting that patients were
commonly prescribed SSRIs without a plan to withdraw:
“it’s all right initiating it, isn’t it, and - but then I
think then there becomes a bit more of a long-term
issue about if you - how long do they stay on them
both? [huh-huh] Do you - which one do you tail off
first? [huh-huh] And erm you don’t - you wouldn’t ne-
cessary want people stuck on both antidepressants for
time immemorial, which sometimes happens with
SSRI, doesn’t it?” [GP102].
Thus, GPs described a future dilemma if antidepres-
sants were combined.
Help-seeking at a point of crisis
Those people who felt they were approached to partici-
pate in the MIR trial when they were at a point of crisis,
described seeing the trial as an opportunity to deal with
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that crisis. Thus, participants detailed the current
impact of their depression on their ability to cope
and to the point where they recognized they needed
help:
“I had a lot of work stress going on as well [uh-huh],
er, and it all got on top of me[…]. I was massively, er,
overeating, erm, oversleeping, permanent low mood,
just generally unwell […] So, er, at, sort of, that point, I
went to the doctor and said, ‘Look, this is what’s going
on. I need some help with this.’”[Male, 52, completer].
Another patient reflects on how his feelings of desper-
ation had led him to accepting referral into the trial by
his GP, in the hope that it would offer alleviation of his
current condition:
“Well I think I was desperate enough to take her
advice that it was more likely to be helpful than
anything, than a hindrance, it wasn’t going to do
any harm and it might do some good” [Male, 83,
completer].
GPs’ accounts reflected the perspectives of patients –
that often help-seeking was at a point of crisis:
“And, and if somebody’s depressed they really - if
they’re, you know, if they’re at a watershed and
they’ve actually come to the doctor’s about it […]
because it’s often a crisis really when they’ve - or
it’s been a huge step to actually come and do
something about it.” [GP102].
“but a lot of the time, when people come and see us,
er, it’s normally at the crisis point” [GP08],
“I think a lot of people by the time they’ve got to us
they’re probably quite sort of… you know, er, they’re
needing some help really.” [GP03].
Such help-seeking at crisis point was not just de-
scribed in new presentations, GPs described how pa-
tients with long-standing mood problems, would often
re-present at a time of crisis:
“Erm, clearly there’s a, quite an imperative to
prescribe in some people, people who have been
unwell for years. Some people want medication and
don’t have the time or the inclination, or the
enthusiasm to go for counselling, for a long period
of time, and wait. They just want something done
now, please.” [GP114].
Discussion
Summary of findings
This qualitative study, embedded within a trial of a com-
bination of two anti-depressants for people with
treatment-resistant depression illustrates patients and
GPs descriptions of the hard work involved in managing
depression; patients described the need to maintain
themselves at an equilibrium, and the importance of a
‘crisis point’ in the precipitation of help-seeking. People
who declined to participate in the MIR trial [17] de-
scribed feeling that they were at an equilibrium, and
feared that participating in the trial would disturb that
hard-won equilibrium. Experiencing a crisis-point
seemed to be a motivator to make a change in manage-
ment, and the offer of trying a second antidepressant
within a trial could act as that motivator to change.
Some ‘decliners’ expressed uncertainties about the role
of medication in the management of depression (even
though they were already taking one antidepressant) and
feared that a second tablet would not help, or could not
see the logic of a second medication.
Those people who participated in the trial (whether
they completed or withdrew) described the persistent
hope that something would help their mood, and this
was something that the participation in the trial offered.
The narratives of GP respondents reflected the patient
data – describing the ‘hard work’ needed to manage
people with depression, how ‘treatment resistance’ was
about more than a poor response to an antidepressant,
but rather about a complex patient presenting the GP a
challenge in management. GPs described how patients
often present at a crisis-point and how the MIR trial of-
fered an option for them to help manage such patients.
Comparison with previous literature
Qualitative research can address questions in trial re-
cruitment that are not easily addressed by quantitative
methods, by providing in-depth information on the ex-
periences of participants and recruiters. [37] The com-
monest reason for people to decline to participate in the
MIR trial [17] was not wanting to take part in a research
study, as described in Barnes et al. qualitative study [31]
nested in a trail of Cognitive Behavioural Therapy
(CBT)for ‘treatment-resistant depression’. But, in con-
trast to Barnes’ qualitative study, where the ‘decliners’
expressed negative feelings about the treatment offered
(CBT) in the trial, in our study ‘decliners’ who were
interviewed, described how they were at an equilibrium
which would be disturbed if they chose to participate in
the trial, although a second antidepressant was not
thought to be logical by a number of the ‘decliners’
interviewed. The patient may be perceived to be resist-
ant to make a further change, having tried out various
strategies and reached a position they were satisfied
Chew-Graham et al. BMC Family Practice          (2018) 19:197 Page 9 of 12
with, and feared losing. This illustrates the difficulty of
the term ‘treatment resistant depression’ – the individual
rather than the depression needs to be considered.
Hughes-Morley et al. [38] described how individuals
declined to participate in a trial because they judged
themselves ineligible or not in need of the trial therapy.
Similarly, our analysis suggests that the ‘decliners’ we
interviewed did not feel that they were in need of the
trial intervention, a second antidepressant. MIR trial
participants described experiencing a crisis as a motiv-
ator to participate in the trial, which resonates with
Schofield et al. (2011) who reported that participants de-
scribed their first course of antidepressants as typically
occurring when they had ‘hit rock bottom’, having
exhausted all other possibilities [39]. Schofield reported
that participants described periods of experimentation
where it was usual to stop and restart medication, often
several times. Ultimately, these recurring cycles lead to
participants becoming more expert about their condition
and better able to make an informed decision about
medication, yet still asking their GP for help. This de-
scription of patient expertise resonates with our analysis.
Schofield also reported that for older people there was
often an acceptance that their condition, and medication
use, would be long term. [39] This acceptance might
resonate with the concept of ‘equilibrium’ we describe
in this study. In a meta-ethnography [30] Malpass and
colleagues (2008) outline the role of the general
practitioner in supporting decision-making about
anti-depressant use, facilitating concordant relationships
with patients regarding antidepressant use. Not having
this discussion at entry into the trial may account for
some people declining to participate. Malpass et al. [30]
recommend that GPs are aware of the competing de-
mands that patients experience at a decision-making
juncture. We identified the importance of a ‘crisis’ in in-
fluencing a decision to try something new, or a sense of
equilibrium in resisting change.
Strengths and limitations
Exploring the reasons for non-participation in trials is
still unusual (and difficult), and this study describes how
such interviews can be incorporated into a trial recruit-
ment procedure. A limitation of the study is that people
who responded to the decliner questionnaire, and invita-
tion to participate in a telephone interview about their
reasons for declining to participate in the MIR trial, were
a self-selected group, which may limit the generalisabil-
ity of the findings. Perhaps people with stronger opin-
ions about the trial might be more likely to respond. In
addition, the telephone interviews were relatively short
(mean duration less than 12min). A strength of this
study was involvement of the PPIE group in the analysis
[36], although some challenges arose, including
difficulties in recruiting a diverse range of members of
the public to participate in the PPIE group, and the re-
search team sometimes experienced difficulties keeping
the PPIE members on track within meetings.
Implications
Collecting information about those who decline to take
part in research is a key way to learn about the accept-
ability of treatments being studied. In pilot studies for
large-scale RCTs, gathering such information may be
useful in refining recruitment estimates. Researchers
recruiting to trials need to be sensitive to the patients’
prior experience of the same (or a similar) intervention
being studied, their feelings about the intervention, and
their views on their potential eligibility.
Similarly, when recruitment takes place with a primary
care consultation, GPs need to explore patients’ reasons
for declining to address any concerns or misconceptions
about the research. This could increase recruitment to
studies and thus ultimately contribute to increasing the
evidence base.
Exploring reasons for declining to participate in a trial
of a second antidepressant for depression suggests that
people who are already taking one antidepressant may
be reluctant to take a second, being wary of possible
side-effects, but also being unconvinced of the logic be-
hind such a combination. In addition, people describe
being in a state of equilibrium and reluctant to make a
change, reflecting that this equilibrium is ‘hard-won’ and
they are unwilling to risk disturbing this.
The importance of achieving and maintaining an ‘equi-
librium’ is a key finding of this qualitative study and
should be incorporated into recruitment strategies in fu-
ture trials of treatments for patients with depression not
responding to an antidepressant, and for whom the
addition of a second antidepressant, or switching an
antidepressant, as suggested by the NICE guideline [12].
A crisis seemed to be the motivator for a patient with
depression to try something new, including agreeing to
take a combination of antidepressants, and this is the
point at which people often consult their GP for help in
routine practice. If a patient receives an invitation to
participate in a trial when they are at such a point, they
may be more willing to participate in the study. Whilst
the MIR trial [17] evaluating the addition of mirtazapine
to an SSRI, did not find convincing evidence of a clinic-
ally important benefit for mirtazapine in addition to an
SSRI or SNRI antidepressant over placebo in primary
care patients who were already on one antidepressant
but remained depressed, it is likely that clinicians will
continue to offer the addition of a second antidepres-
sant, including mirtazapine, to patients with so called
‘treatment-resistant depression’. It is vital that the GP
explores with the patient their views on antidepressants,
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what other strategies they have tried to manage their
symptoms, and whether the patient feels they are at a
point of crisis or equilibrium. This has implications for
the education and training of GPs about the management
of depression in primary care, and the importance of regu-
lar review and monitoring for people with depression.
Conclusions
Understanding a patient’s view on medication is import-
ant for GPs when discussing antidepressants in the rou-
tine primary care consultation when a diagnosis of
depression has been made and agreed. Understanding
patients’ self-management strategies and what has pre-
cipitated their consultation is key to negotiating appro-
priate and acceptable management strategies.
Abbreviations
CBT: Cognitive Behavioural Therapy; GP : General Practitioner; MIR
trial: Mirtazapine added to SSRIs or SNRIs for treatment resistant depression
in primary care: phase III randomised controlled trial; UK: United Kingdom
Acknowledgements
The authors would like to thank the participants who took part in this study,
for their time and valuable contributions. The authors would like to thank
the rest of the MIR trial team, participating practice, and the PPIE group.
Funding
This study was funded by the National Institute for Health Research Health
Technology Assessment programme (project number 11/129/76). The views
and opinions expressed here are those of the authors and do not necessarily
reflect those of the HTA programme, NIHR, NHS or the Department of Health.
Availability of data and materials
The datasets generated and/or analysed during the current study are not
publicly available, but are securely stored, and may be available from the
corresponding author on reasonable request.
Authors’ contributions
KD conducted interviews with participants. KD, HB and CACG participated in
data analysis.
CACG drafted the manuscript, and all authors contributed to draft versions
of the manuscript, and approved the final version.
Ethics approval and consent to participate
Ethics approval was received from the South East Wales Research Ethics
Committee (reference number 12/WA/0350. Consent was received from all
participants prior to data collection.
Consent for publication
Consent was received from all participants to publish the findings from this
study. Consent was also received for the publication of pseudonymised
direct quotes.
Competing interests
The authors declare that they have no competing interests.
Publisher’s Note
Springer Nature remains neutral with regard to jurisdictional claims in
published maps and institutional affiliations.
Author details
1Research Institute, Primary Care and Health Sciences, Keele University,
Newcastle, Staffs ST5 5BG, UK. 2Centre for Academic Primary Care, Oakfield
House, Oakfield Grove, Clifton, Bristol BS8 2BN, UK.
Received: 13 January 2018 Accepted: 19 November 2018
References
1. Global Burden of Disease Study 2015. Global Burden of Disease Study 2015
(GBD 2015) Reference Life Table. Seattle: United States: Institute for Health
Metrics and Evaluation (IHME); 2016.
2. Evans DL, Charney DS, Lewis L, Golden RN, Gorman JM, Krishnan KRR, et al.
Mood disorders in the medically ill: scientific review and recommendations.
Biol Psychiatry [Internet]. Elsevier; 2005 Aug 1 [cited 2014 May 26];58(3):175–
89. Available from: http://www.biologicalpsychiatryjournal.com/article/
S0006322305005743/fulltext.
3. van’t Veer-Tazelaar PJ, van Marwijk HWJ, Jansen APD, Rijmen F, Kostense PJ,
van Oppen P, et al. Depression in old age (75+), the PIKO study. J Affect
Disord [Internet]. 2008 Mar [cited 2014 May 27];106(3):295–9. Available from:
http://www.sciencedirect.com/science/article/pii/S016503270700256X.
4. Katon W, Ciechanowski P. Impact of major depression on chronic medical
illness. J Psychosom Res [Internet]. 2002 Oct [cited 2014 May 27];53(4):859–
63. Available from: http://www.sciencedirect.com/science/article/pii/
S0022399902003136.
5. Thompson C, Ostler K, Peveler RC, et al. Dimensional perspective on the
recognition of depressive symptoms in primary care. Br J Psychiatry. 2001;
179:317–23.
6. Kirmayer LJ, Robbins JM, Dworkind M, et al. Somatization and the
recognition of depression and anxiety in primary care. Am J Psychiatr. 1993;
150:734–41.
7. Tylee A, Freeling P, Kerry S, et al. How does the content of consultations
affect the recognition by general practitioners of major depression in
women? Br J Gen Pract. 1995;45:575–8.
8. Goldberg D, Privett M, Ustun B, et al. The effects of detection and treatment
on the outcome of major depression in primary care: a naturalistic study in
15 cities. Br J Gen Pract. 1998;48:1840–4.
9. Kessler D, Bennewith O, Lewis G, et al. Detection of depression and anxiety
in primary care: follow up study. BMJ. 2002;325:1016–7.
10. Lancet Global Mental Health Group. Scale up services for mental disorders:
a call for action. Lancet. 2007;370:1241–52.
11. Mental Health Foundation. (2016). Fundamental facts about mental health 2016.
Mental Health Foundation: London. https://www.mentalhealth.org.uk/
publications/fundamental-facts-about-mental-health-2016. (accessed 06/11/2018).
12. National Institute for Health and Clinical Excellence, editor. THE NICE
GUIDELINE ON THE TREATMENT AND DEPRESSION THE TREATMENT AND
MANAGEMENT OF DEPRESSION IN ADULTS UPDATED EDITION. Updated Ed.
London: The British Psychological Society and the Royal College of
Psychiatrists; 2009.
13. Philp FMPWAR. Primary care-based guided self-help for depression provided
by a nurse practitioner: a pilot evaluation. Prim Care Ment Heal Jul. 2006;
4(3):159.
14. Yohannes AM. General practitioners views and experiences in managing
depression in patients with chronic obstructive pulmonary disease. Expert
Rev Respir Med [Internet]. Informa HealthcareLondon; 2012 Dec 9 [cited
2014 May 27];6(6):589–95. Available from: http://informahealthcare.com/doi/
abs/10.1586/ers.12.64.
15. Prescribing and Medicines Team. Health and Social Care Information Centre.
Prescriptions dispensed in the Community: England; 2015. p. 2004–14.
16. Trivedi M, Rush A, Wisniewski S, Nierenberg A, Warden D, Ritz L, et al.
Evaluation of outcomes with citalopram for depression using measurement-
based care in STAR*D: implications for clinical practice. Am J Psychiatry.
2006;163:28–40.
17. Kessler D, Macneill Tallon D, Lewis G, Peters TJ, Hollingworth W, Round J,
Burns A, Chew-Graham CA, Anderson IN, Shepherd T, Campbell J, Dickens
CM, Carter M, Jenkinson C, Macleod U, Gibdson S, Wiles NJ. Mirtazapine
added to SSRIs or SNRIs for treatment resistant depression in primary care:
phase III randomised controlled trial (MIR). BMJ. 2018;363:k4218.
18. Snowden A, Marland G. No decision about me without me: concordance
operationalised. J Clin Nurs [Internet]. 2013 May [cited 2013 Oct 24];22(9–10):
1353–60. Available from: http://www.ncbi.nlm.nih.gov/pubmed/23121664.
19. Moradveisi L, Huibers M, Renner F, Arntz A. The influence of patients’
preference/attitude towards psychotherapy and antidepressant medication
on the treatment of major depressive disorder. J Behav Ther Exp Psychiatry
[Internet]. 2014 Mar [cited 2014 Jan 28];45(1):170–7. Available from: http://
www.sciencedirect.com/science/article/pii/S0005791613000773.
Chew-Graham et al. BMC Family Practice          (2018) 19:197 Page 11 of 12
20. Brown C, Battista DR, Bruehlman R, Sereika SS, Thase ME, Dunbar-Jacob J.
Beliefs about antidepressant medications in primary care patients:
relationship to self-reported adherence. Med Care [Internet]. 2005 Dec [cited
2014 Dec 9];43(12):1203–7. Available from: http://www.ncbi.nlm.nih.gov/
pubmed/16299431.
21. Lam RW. Patients’ preferences and counselling for depression in primary
care. Lancet [Internet]. 2001 24 [cited 2014 Dec 9];357(9256):575–6. Available
from: http://www.sciencedirect.com/science/article/pii/S0140673600040769.
22. Van Schaik DJF, Klijn AFJ, van Hout HPJ, van Marwijk HWJ, Beekman ATF, de
Haan M, et al. Patients’ preferences in the treatment of depressive disorder
in primary care. Gen Hosp Psychiatry [Internet]. [cited 2014 Nov 28];26 (3):
184–9. Available from: http://www.ncbi.nlm.nih.gov/pubmed/15121346.
23. Prins M A, Verhaak PFM, Bensing JM, van der Meer K. Health beliefs and
perceived need for mental health care of anxiety and depression--the
patients’ perspective explored. Clin Psychol Rev [Internet]. 2008 Jul [cited
2013 Nov 20];28(6):1038–58. Available from: http://www.ncbi.nlm.nih.gov/
pubmed/18420323.
24. Houle J, Villaggi B, Beaulieu M-D, Lespérance F, Rondeau G, Lambert J.
Treatment preferences in patients with first episode depression. J Affect
Disord [Internet]. 2013 May [cited 2013 Nov 20];147(1–3):94–100. Available
from: http://www.ncbi.nlm.nih.gov/pubmed/23167975.
25. Gum AM, Arean PA, Hunkeler E, Tang L, Katon W, Hitchcock P, et al.
Depression Treatment Preferences in Older Primary Care Patients.
Gerontologist [Internet]. 2006 1 [cited 2014 May 28];46(1):14–22. Available
from: http://gerontologist.oxfordjournals.org/content/46/1/14.full.
26. Givens JL, Datto CJ, Ruckdeschel K, Knott K, Zubritsky C, Oslin DW, et al.
Older patients’ aversion to antidepressants. A qualitative study. J Gen Intern
Med [Internet]. 2006 Feb [cited 2013 Oct 24];21(2):146–51. Available from:
http://www.pubmedcentral.nih.gov/articlerender.fcgi?artid=1484662&tool=
pmcentrez&rendertype=abstract.
27. Verbeek-Heida PM, Mathot EF. Better safe than sorry — why patients prefer
to stop using selective serotonin reuptake inhibitor (SSRI) antidepressants
but are afraid to do so: results of a qualitative study. Chronic Illn [Internet].
2006 1 [cited 2014 May 29];2(2):133–42. Available from: https://www.ncbi.
nlm.nih.gov/pubmed/17175656.
28. Van Geffen ECG, Hermsen JHCMJHCM, Heerdink ER, Egberts ACG, Verbeek-
Heida PM, Van Hulten R. The decision to continue or discontinue treatment:
Experiences and beliefs of users of selective serotonin-reuptake inhibitors in
the initial months-A qualitative study. Res Soc Adm Pharm [Internet].
Division of Pharmacoepidemiology and Pharmacotherapy, Faculty of
Science, Utrecht Institute for Pharmaceutical Sciences (UIPS), Utrecht
University, PO Box 80082, 3508 TB, Utrecht, Netherlands: Elsevier Inc; 2011
Jun [cited 2014 May 28];7(2):134–50. Available from: http://www.ncbi.nlm.
nih.gov/pubmed/21272543.
29. Leydon GM, Rodgers L, Kendrick T. A qualitative study of patient views on
discontinuing long-term selective serotonin reuptake inhibitors. Fam Pract
[Internet]. 2007 [cited 2014 Dec 9];24(6):570–5. Available from: http://www.
ncbi.nlm.nih.gov/pubmed/18032401.
30. Malpass A, Shaw A, Sharp D, Walter F, Feder G, Ridd M, et al. “Medication
career” or “moral career”? The two sides of managing antidepressants: a
meta-ethnography of patients’ experience of antidepressants. Soc Sci Med
[Internet]. 2009 [cited 2013 Oct 24];68(1):154–68. Available from: http://
www.ncbi.nlm.nih.gov/pubmed/19013702.
31. Barnes M, Wiles N, Morrison J, Kessler D, Williams C, Kuyken W, et al.
Exploring patients’ reasons for declining contact in a cognitive behavioural
therapy randomised controlled trial in primary care. Br J Gen Pract
[Internet]. 2012 May [cited 2014 May 28];62(598):e371–7. Available from:
http://www.pubmedcentral.nih.gov/articlerender.fcgi?artid=3338059&tool=
pmcentrez&rendertype=abstract.
32. O’Cathain A, Thomas KJ, Drabble SJ, Rudolph A, Goode J, Hewison J.
Maximising the value of combining qualitative research and randomised
controlled trials in health research: the QUAlitative Research in Trials (QUART)
study – a mixed methods study. Health Technol Assess. 18(38):1–197.
33. Braun V, Clarke V. Using thematic analysis in psychology. Qual Res Psychol.
2006;3(2):77–101.
34. Henwood KL, Pidgeon NF. Qualitative research and psychological
theorizing. Br J Psychol. 1992;83:97–111.
35. NVivo. qualitative data analysis Software: QSR International Pty Ltd.
Version 10; 2012. https://www.qsrinternational.com/nvivo/what-is-nvivo.
36. Garfield S, Jheeta S, Husson F, Jackline A, Bischler A, Norton C, Franklin BD.
Lay involvement in the analysis of qualitative data in health services
research: a descriptive study. Res Involv Engagem. 2016;2:29. https://doi.org/
10.1186/s40900-016-0041-z.
37. Hennessy M, Hunter A, Healy P, Galvin S, Houghton C. Improving trial
recruitment processes: how qualitative methodologies can be used to
address the top 10 research priorities identifiedwithin the PRioRiTy study.
Trials. 2018;19(584). https://doi.org/10.1186/s13063-018-2964-1.
38. Hughes-Morley A, Young B, Hempel RJ, Russell I, Waheed W, Bower P. What
can we learn from trial decliners about improving recruitment? Qualitative
study. BMC Trials. 2016;17:494 https://www.ncbi.nlm.nih.gov/pubmed/
27733181.
39. Schofield P, Crosland A, Waheed W, Aseem S, Gask L, Wallace A, Dickens A,
Tylee A. Patients’ views of antidepressants: From first experiences to
becoming expert. British Journal of General Practice. 2011;61(252–253).
https://doi.org/10.3399/bjgp11X567045.
Chew-Graham et al. BMC Family Practice          (2018) 19:197 Page 12 of 12
